Science technology company Manhattan Scientifics Inc (OTCQB: MHTX), the initial funder and owner of over 50 million shares of Imagion Biosystems Ltd, a developer of a non-radioactive and highly sensitive diagnostic imaging technology, announced on Wednesday that Imagion has reached significant milestones in early cancer detection technology.
Imagion introduced groundbreaking imaging agent technology in 2022, demonstrating safety in Phase 1 studies with real breast cancer patients. The company also pioneered a clinical study utilising magnetic nanoparticles for targeted cancer imaging, revolutionising non-invasive cancer detection.
In 2023, independent validation confirmed two crucial findings from Imagion's Phase 1 data, reinforcing its focus on using MRI for molecular imaging of cancer. This approach offers a faster and more cost-effective path to commercialise its imaging agents.
In addition, Imagion is in discussions with the U.S. FDA to advance its MagSense HER2 development for breast cancer detection into Phase 2 studies. Despite challenges, Imagion remains confident that progress is not adequately reflected in the current share price.
To sustain its technological advancements, Imagion also secured a financing agreement with Mercer Street Capital and will USD3.5m in funding this quarter through its ATO tax credit, ensuring steady access to working capital.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study